Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report

Kidney International

Volumn 64, Issue 2, 2003, Pages 451-458

  Riser, Bruce L ^a,c   Cortes, Pedro ^a   DeNichilo, Mark ^a,b   Deshmukh, Poornima V ^a   Chahal, Parminder S ^a   Mohammed, Ali K ^a   Yee, Jerry ^a   Kahkonen, Dorothy ^a  

^a Henry Ford Health Science Center   (United States)

^b TGR BioSciences   (Australia)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Chronic kidney disease; Diagnostic; Prognostic indicator; Renal fibrosis

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HUMAN; HYPOTHESIS; KIDNEY FAILURE; KIDNEY FIBROSIS; MALE; MICROALBUMINURIA; NONHUMAN; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RAT; TIME; UPREGULATION; VOLUNTEER; WESTERN BLOTTING;

EID: 0038119587     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00130.x     Document Type: Article

References (37)

1. DORMAN JS, LAPORTE RE, KULLER LH, et al: The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 33:271-276, 1984
2. ANDERSEN AR, CHRISTIANSEN JS, ANDERSEN JK, et al: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25:496-501, 1983
3. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
4. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
5. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
6. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
7. PARVING HH, HOMMEL E: Prognosis in diabetic nephropathy. Br Med J 299:230-233, 1989
8. STEHOUWER CD, NAUTA JJ, ZELDENRUST GC, et al: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319-323, 1992
9. BOJESTIG M, ARNQVIST HJ, KARLBERG BE, LUDVIGSSON J: Glycemic control and prognosis in type I diabetic patients with microalbuminuria. Diabetes Care 19:313-317, 1996
10. MOGENSEN CE, KEANE WF, BENNETT PH, et al: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
11. RUGGENENTI P, REMUZZI G: Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol 9:2157-2169, 1998
12. FIORETTO P, STEFFES MW, SUTHERLAND DE, MAUER M: Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progression. Kidney Int 48:1929-1935, 1995
13. AYER-LELIEVRE C, BRIGSTOCK D, LAU L, et al: Report and abstracts on the first international workshop on the CCN family of genes. Mol Pathol 54:105-120, 2001
14. BRADHAM DM, IGARASHI A, POTTER RL, GROTENDORST GR: Connective tissue growth factor: A cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114:1285-1294, 1991
15. BORK P: The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 327:125-130, 1993
16. ITO Y, ATEN J, BENDE RJ, et al: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853-861, 1998
17. RISER BL, DENICHILO M, CORTES P, et al: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25-38, 2000
18. RISER BL, CORTES P, ZHAO X, et al: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90:1932-1943, 1992
19. RISER BL, CORTES P, YEE J: Modelling the effects of vascular stress in mesangial cells. Curr Opin Nephrol Hypertens 9:43-47, 2000
20. HOCHBERG Y, BENJAMINI Y: More powerful procedures for multiple significance testing. Stat Med 8:811-818, 1990
21. WELCH B: On the comparison of several mean values: An alternative approach. Biometrika 38:330-336, 1951
22. SATTERTHWAITE FE: An approximate distribution of estimates of variance components. Biometrics Bull 2:110-114, 1946
23. MURPHY M, GODSON C, CANNON S, et al: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274:5830-5834, 1999
24. RISER BL, CORTES P: Connective tissue growth factor and its regulation: A new element in diabetic glomerulosclerosis. Ren Fail 23:459-470, 2001
25. ADLER SG, KANG SW, FELD S, et al: Glomerular mRNAs in human type 1 diabetes: Biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int 60:2330-2336, 2001
26. STEFFEN CL, BALL-MIRTH DK, HARDING PA, et al: Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. Growth Factors 15:199-213, 1998
27. BALL DK, SURVEYOR CA, DIEHL JR, et al: Characterization of 16- to 20-kilodalton (kDa) connective tissue growth factors (CTGFs) and demonstration of proteolytic activity for 38-kDa CTGF in pig uterine luminal flushings. Biol Reprod 59:828-835, 1998
28. FRAZIER KS, PAREDES A, DUBE P, STYER E: Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol 37:328-335, 2000
29. HEUSINGER-RIBEIRO J, EBERLEIN M, WAHAB NA, GOPPELT-STRUEBE M: Expression of connective tissue growth factor in human renal fibroblasts: Regulatory roles of RhoA and cAMP. J Am Soc Nephrol 12:1853-1861, 2001
30. EBIHARA I, NAKAMURA T, SHIMADA N, KOIDE H: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 32:544-550, 1998
31. ELLIS D, FORREST KY, ERBEY J, ORCHARD TJ: Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: Application in diabetic nephropathy. Clin Chem 44:950-956, 1998
32. BOLLINENI JS, REDDI AS: Transforming growth factor-beta 1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 42:1673-1677, 1993
33. BORDER WA, NOBLE NA: TGF-beta in kidney fibrosis: A target for gene therapy. Kidney Int 51:1388-1396, 1997
34. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
35. CHEN S, COHEN MP, ZIYADEH FN: Amadori-glycated albumin in diabetic nephropathy: Pathophysiologic connections. Kidney Int 77:S40-44, 2000
36. RISER BL, CORTES P, YEE J, et al: Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: Role of TGF-beta. J Am Soc Nephrol 9:827-836, 1998
37. SHARMA K, ZIYADEH FN, ALZAHABI B, et al: Increased renal production of transforming growth factor-betal in patients with type II diabetes. Diabetes 46:854-859, 1997